PHGE - BiomX Inc.

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
0.63 0.0 (0.16%)	---	---	---	0.0 (-0.02%)	-0.02 (-2.37%)	0.0 (0.78%)	0.0 (0.78%)

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: 0.33
Diluted EPS:: 0.33
Basic P/E:: 1.9085
Diluted P/E:: 1.9085
RSI(14) 1m:: 0.0
VWAP:: 0.63
RVol:: 0.8071

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	0.63 +0.01 (+1.56%)	Oct 15 10:16
10m	Price increase 10m	0.64 +0.02 (+3.18%)	Oct 15 10:14
1m	Price increase 1m	0.64 +0.01 (+1.57%)	Oct 15 10:01
1m	Price decrease 1m	0.62 -0.01 (-1.6%)	Oct 15 10:00
1m	Price decrease 1m	0.64 -0.01 (-1.35%)	Oct 15 09:34